https://www.live-feeds.com/feed/new-drug-shows-promise-in-reducing-copd-symptoms-in-former-and-current-smokers-clinical-trials-showContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/new-drug-shows-promise-in-reducing-copd-symptoms-in-former-and-current-smokers-clinical-trials-showhttps://www.live-feeds.com/feed/new-drug-shows-promise-in-reducing-copd-symptoms-in-former-and-current-smokers-clinical-trials-show#u63225Wed, 09 Sep 2026 23:00:29 +0000AstraZeneca's investigational biologic therapy, tozorakimab, significantly reduced moderate and severe COPD exacerbations in two late-stage clinical trials named OBERON and TITANIA. The drug showed benefits across various patient groups, including current and former smokers who continued to experience flare-ups despite receiving standard inhaled care. Data presented at ERS 2026 indicate the IL-33 antibody provides a clinically meaningful reduction in exacerbations when added to standard treatment. AstraZeneca R&D chief Barr described the results as an internal science success story, b